A digitally delivered dual-task training (DTT) program was just as good as a standard physical therapist-led one at improving gait in people with Parkinson’s disease, a small clinical trial suggests. Eight-week DTT programs, which are designed to improve patients’ ability to multitask when moving, led to significantly increased gait…
Activating the Nurr1 protein eased both motor and smell deficits and showed neuroprotective properties in mouse and cell models of Parkinson’s disease in a recent study. The newly developed Nurr1 activator, called 4A7C-301, also did not induce dyskinesia, the involuntary movements associated with certain standard Parkinson’s treatments,…
Internalized, experienced, or anticipated stigma have significant impacts on employment experiences for people with Parkinson’s disease, according to a recent study. In semi-structured interviews with patients, a researcher identified that patients felt hesitant to disclose their diagnosis in the workplace or ask for disability-related accommodations, often due to a…
Higher levodopa doses were associated with a drop in blood pressure among older Parkinson’s patients, those with 65 or more years, in the early and middle stages of the disease, a study reported. Cognitive impairment was identified as a risk factor for a sudden blood pressure drop when…
An approach for treating dysphagia — called effortful swallow maneuver — did not consistently ease signs of swallowing difficulties for Parkinson’s disease patients in a small pilot study. Effortful swallow, or ES, refers to a practice where patients are asked to consciously increase the force they use when swallowing…
Changes in vision and eye health prior to deep brain stimulation (DBS) surgery can be a significant predictor of delirium in the hours after this Parkinson’s disease surgery, a study suggests. A post-operative risk of the psychiatric condition was found to be greater in older patients and those with…
Researchers have uncovered new evidence that activity in the gut can directly influence brain function, a relationship that’s been proposed to contribute to Parkinson’s disease. Using specialized fibers with the ability to stimulate nerve cells with light, called optogenetics, the scientists found that by altering cell activity in the…
Certain biomarkers in the blood may help doctors in determining whether a person has Parkinson’s disease or atypical parkinsonism, both of which show similar symptoms, a study reported. Three biomarkers — neurofilament light chain (NfL) and malondialdehyde (MDA), particularly, but also 24S-hydroxycholesterol (24S-HC) — were found at significantly…
A history of using inhaled beta-2 adrenoceptor (B2AR) agonists to treat asthma or chronic obstructive pulmonary disorder (COPD) was not associated with a decreased risk of developing Parkinson’s disease, according to a recent Finnish study. The findings contrast earlier epidemiological studies that found these medications, commonly used to treat…
Following promising new data from healthy volunteers in early clinical trials, NodThera now is testing its oral treatment candidate NT-0796 in a Phase 1b/2a biomarker study involving people with Parkinson’s disease. The biotech company announced the positive results from its first-in-human Phase 1 study (ACTRN12621001082897), which found…
Get regular updates to your inbox.
